Abstract：Objective To investigate the possibility of the improved intravenous thrombolytic therapy for the acute cerebral infarction with urokinase.Methods 56 cases of patients with acute cerebral infarction from January 2013 to March 2014 were randomly divided into traditional urokinase thrombolysis group （quick delivery）with 28 cases and improved urokinase thrombolysis group（slow delivery）with 28 cases.The traditional urokinase thrombolysis group was given conventional intravenous thrombolytic therapy with urokinas，and the improved urokinase thrombolysis group was given improved intravenous thrombolytic therapy with urokinase.The clinical effect of two groups were compared.Results NIHSS scores of the treatment group were significantly decreased after using urokinase at 3，7，14，30 d （P＜0.05）.BI scores of the treatment group were significantly increased after 7，14 d （P＜0.05）.The total effective rate in the improved urokinase thrombolysis group was 92.86%，which was higher than 82.14%of the traditional urokinase thrombolysis group，and the difference were statistically significant（P＜0.05）.The security was increased significantly in modified urokinase thrombolysis group compared with that in traditional urokinase thrombolysis group.Conclusion The improved intravenous thrombolytic therapy for acute cerebral infarction is a kind of safe and effective method.
Nakashima T，Minematsu K.Prospects of thrombolytic therapy for acute ischemic stroke［J］.Brain Nerve，2009，61（9）：1003-1012.
［4］
Murao K，Leys D，Jacquin A.Thrombolytic therapy for stroke in patients with pre-existing cognitive impairment［J］.Neurology，2014，14（10）：493.
［5］
Mehrpour M，Aghaei M，Motamed MR.Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke［J］.Med J Islam Repub Iran，2013，27（3）：113-118.
Lanitis T，Cotté F，Gaudin A.Stroke prevention in patients with atrial fibrillation in France：comparative cost-effectiveness of new oral anticoagulants（apixaban，dabigatran and rivaroxaban），warfarin and aspirin［J］.J Med Econ，2014，15（1）：30-31.
［9］
Marián MD，Marta R，David RL，et al.Baseline national institutes of health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke［J］.Stroke，2014，45（1）：1059-1063.
［10］
Liesbet DW，Koen P，Hannes D，et al.Long-term prediction of functional outcome after stroke using single items of the Barthel Index at discharge from rehabilitation centre［J］.Disabil Rehabil，2014，36（5）：353-358.
［11］
Bandera E，Botterri M，Minelli C，et al.Cerebral blood flow threshold of ischemic punumbra and infarct core in acute ischemic stroke：a systematic review［J］.Stroke，2006，37（5）：1334-1339.
Jauch EC，Saver JL，Adams HP，et al.Guidelines for the early managementofpatientswith acute ischemic stroke：a guideline for health care professionals from the American Heart Association/American Stroke Association［J］.Stroke，2013，44（1）：870-947.
Yamaguchi T，Mori E，Minematsu K，et al.Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset：Japan Alteplase Clinical Trial（J-ACT）［J］.Stroke，2006，37（7）：1810-1815.
京公网安备 11010502046607号